Abstract 472: Biologic Therapy Improves Lipid-rich Necrotic Core With Concomitant Reduction In S100A8/A9 In Psoriasis: Results From A Prospective, Observational Study
| العنوان: | Abstract 472: Biologic Therapy Improves Lipid-rich Necrotic Core With Concomitant Reduction In S100A8/A9 In Psoriasis: Results From A Prospective, Observational Study |
|---|---|
| المؤلفون: | Christin G Hong, Alexander R Berg, Philip M Parel, Elizabeth Florida, Ross O'Hagan, Carla J Pantoja, Haiou Li, Wunan Zhou, Alexander V Sorokin, Heather Teague, Martin Playford, Andrew Buckler, Nehal N Mehta |
| المصدر: | Arteriosclerosis, Thrombosis, and Vascular Biology. 42 |
| بيانات النشر: | Ovid Technologies (Wolters Kluwer Health), 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Cardiology and Cardiovascular Medicine |
| الوصف: | Introduction: S100A8/A9 is an alarmin protein complex secreted by activated neutrophils in response to inflammation and associated with atherosclerosis and cardiovascular disease. Psoriasis is a chronic inflammatory disease linked with increased levels of S100A8/A9, elevated atherosclerotic risk, and premature cardiovascular disease. Lipid-rich necrotic core (LRNC) is a high-risk coronary plaque feature predictive of future cardiovascular events with increased prevalence in psoriasis. Whether S100A8/A9 associates with LRNC is understudied. We aimed to characterize the relationship between S100A8/A9 and LRNC pre- and post-initiation of biologic therapy in psoriasis over 1 year. Methods: Participants were part of an ongoing cohort study of 320 consecutive patients, of whom 125 had comprehensive measurement of S100 proteins by enzyme-linked immunosorbent assay and quantifiable coronary computed tomography angiography scans. LRNC was measured using Elucid Bioimaging software. Results: S100A8/A9 positively associated with neutrophils (R=0.19, P =0.03) and inflammatory markers GlycA (R=0.30, P =0.001) and hs-CRP (R=0.24, P =0.005). Only S100A8/A9 associated with LRNC area (β=0.19, P =0.03) beyond adjustment for cardiovascular risk factors, statin use, biologic therapy, and neutrophils (β=0.22, P =0.02) ( Figure 1A ). Over 1 year, biologic therapy reduced S100A8/A9 levels by 79% (-197 (-320-21.4) vs -42.3 (-167.2-50.5); P =0.04) ( Figure 1B ) and decreased LRNC area by 0.6 mm 2 (0.04 (-0.48-0.77) vs -0.56 (-1.8-0.13); P =0.02) ( Figure 1C ). Conclusion: Of the S100 family, the S100A8/A9 heterodimer uniquely associated with LRNC in fully adjusted models. Further, biologic therapy over 1 year reduced LRNC area concomitantly with S100A8/A9 in psoriasis. These findings underscore the impact of the S100 family in high-risk coronary plaque development and support the need for mechanistic studies to better elucidate these findings. |
| تدمد: | 1524-4636 1079-5642 |
| DOI: | 10.1161/atvb.42.suppl_1.472 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::08c4d4ff2aa21a1344cc149074c09ed0 https://doi.org/10.1161/atvb.42.suppl_1.472 |
| رقم الانضمام: | edsair.doi...........08c4d4ff2aa21a1344cc149074c09ed0 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15244636 10795642 |
|---|---|
| DOI: | 10.1161/atvb.42.suppl_1.472 |